• Drug levels required to improve clinical outcomes may vary between patients and depend on the desired therapeutic endpoint   
  • In patients with undetectable drug levels, anti-drug antibody (ADAb) quantification helps to identify how to improve patient response
  • In patients with high anti-drug antibodies levels, a switch in-class may be necessary
  • In patients with low anti-drug antibodies levels, the addition of an immunosuppressive drug may improve clinical outcomes